A common solution to group 2 influenza virus neutralization

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 1, 2014, Pages 445-450

  Friesen, Robert H E ^a   Lee, Peter S ^b   Stoop, Esther J M ^a   Hoffman, Ryan M B ^b   Ekiert, Damian C ^b,d   Bhabha, Gira ^b,e   Yu, Wenli ^b   Juraszek, Jarek ^a   Koudstaal, Wouter ^a   Jongeneelen, Mandy ^a   Korse, Hans J W M ^a   Ophorst, Carla ^a   Brinkman Van Der Linden, Els C M ^a   Throsby, Mark ^a,f   Kwakkenbos, Mark J ^c   Bakker, Arjen Q ^c   Beaumont, Tim ^c   Spits, Hergen ^c   Kwaks, Ted ^a   Vogels, Ronald ^a   Ward, Andrew B ^b   Goudsmit, Jaap ^a   Wilson, Ian A ^b   more..

^a CRUCELL HOLLAND BV   (Netherlands)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c AIMM Therapeutics   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Merus BV   (Netherlands)

Author keywords

Antibody recognition; Electron microscopy; X ray crystallography

Indexed keywords

CR 8020; CR 8043; CR 8057; EPITOPE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H10N7; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H7N7; LETHAL DOSE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

ANTIBODY RECOGNITION; ELECTRON MICROSCOPY; X-RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHROMATOGRAPHY, GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS; INFLUENZA VACCINES; KINETICS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SPECIES SPECIFICITY;

EID: 84891910969     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1319058110     Document Type: Article

References (38)

1. World Health Organization (WHO) (2009) Fact Sheet 211: Influenza (World Health Organization, Geneva).
2. Potter CW (2001) A history of influenza. J Appl Microbiol 91(4): 572-579.
3. Stephenson I, et al. (2009) Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 48(4): 389-396.
4. Carrat F, Flahault A (2007) Influenza vaccine: The challenge of antigenic drift. Vaccine 25(39-40): 6852-6862.
5. Palladino G, Mozdzanowska K, Washko G, Gerhard W (1995) Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 69(4): 2075-2081.
6. Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese K (1997) Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 159: 95-103.
7. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289(5796): 373-378.
8. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 69: 531-569.
9. Whittle JR, et al. (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 108(34): 14216-14221.
10. Ekiert DC, et al. (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489(7417): 526-532.
11. Lee PS, et al. (2012) Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci USA 109(42): 17040-17045.
12. Tsibane T, et al. (2012) Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog 8(12):e1003067.
13. Xu R, et al. (2013) A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol 20(3): 363-370.
14. Schmidt AG, et al. (2013) Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci USA 110(1): 264-269.
15. Hong M, et al. (2013) Antibody recognition of the pandemic H1N1 influenza virus hemagglutinin receptor binding site. J Virol 87(22): 12471-12480.
16. Kashyap AK, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105(16): 5986-5991.
17. Throsby M, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered fromhuman IgM+memory B cells. PLoS One 3(12):e3942.
18. Sui J, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16(3): 265-273.
19. Ekiert DC, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924): 246-251.
20. Corti D, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120(5): 1663-1673.
21. Ekiert DC, et al. (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333(6044): 843-850.
22. Corti D, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333(6044): 850-856.
23. De Marco D, et al. (2012) A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS One 7(4):e34415.
24. Dreyfus C, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337(6100): 1343-1348.
25. Dreyfus C, Ekiert DC, Wilson IA (2013) Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J Virol 87(12): 7149-7154.
26. Wrammert J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J ExpMed 208(1): 181-193.
27. Ekiert DC, Wilson IA (2012) Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol 2(2): 134-141.
28. Burton DR, Poignard P, Stanfield RL, Wilson IA (2012) Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337(6091): 183-186.
29. Julien JP, Lee PS, Wilson IA (2012) Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev 250(1): 180-198.
30. Kwakkenbos MJ, et al. (2010) Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 16(1): 123-128.
31. Arnaout R, et al. (2011) High-resolution description of antibody heavy-chain repertoires in humans. PLoS One 6(8):e22365.
32. Burton DR (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2(9): 706-713.
33. Kong L, et al. (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20(7): 796-803.
34. Margine I, et al. (2013) H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol 87(8): 4728-4737.
35. Wang TT, et al. (2010) Broadly protectivemonoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6(2): e1000796.
36. Azoitei ML, et al. (2011) Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334(6054): 373-376.
37. Azoitei ML, et al. (2012) Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J Mol Biol 415(1): 175-192.
38. Skehel JJ, Wiley DC (2002) Influenza haemagglutinin. Vaccine 20(Suppl 2):S51-S54.